Citadel Advisors
KLRS

Citadel Advisors’s Kalaris Therapeutics KLRS Stock Holding History

Citadel Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,674
Closed -$64.5K – 15893
2024
Q4 		$64.5K Buy
6,674
+3,013
+82% +$45.6K ﹤0.01% 12092
2024
Q3 		$68.1K Sell
3,661
-1,003
-22% -$17.5K ﹤0.01% 11595
2024
Q2 		$77.6K Sell
4,664
-1,693
-27% -$29.9K ﹤0.01% 11253
2024
Q1 		$110K Sell
6,357
-4,072
-39% -$66.4K ﹤0.01% 11216
2023
Q4 		$163K Buy
+10,429
New +$411K ﹤0.01% 10255
2023
Q3 		– Sell
-11,155
Closed -$760K – 15290
2023
Q2 		$872K Buy
11,155
+8,820
+378% +$838K ﹤0.01% 6745
2023
Q1 		$212K Sell
2,335
-1,047
-31% -$133K ﹤0.01% 10083
2022
Q4 		$399K Buy
+3,382
New +$574K ﹤0.01% 8722
2022
Q2 		– Sell
-4,737
Closed -$497K – 14323
2022
Q1 		$736K Buy
4,737
+2,123
+81% +$424K ﹤0.01% 8444
2021
Q4 		$778K Buy
+2,614
New +$1.21M ﹤0.01% 8566
2020
Q4 		– Sell
-1,674
Closed -$1.06M – 11640
2020
Q3 		$1.06M Buy
+1,674
New +$1.14M ﹤0.01% 5935

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's KLRS Position: Q1 2025 in Review

Citadel Advisors sold out of Kalaris Therapeutics (KLRS) in Q1 2025, closing a stake of 6,674 shares — an estimated $64.5K sold.

Citadel Advisors first reported a position in KLRS in Q3 2020 and held it in 11 quarters. The position peaked at $1.06M in Q3 2020. 32 funds tracked by Wall St. Rank hold KLRS as of Q1 2025.

  • Citadel Advisors reported no remaining Kalaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 6,674 Kalaris Therapeutics shares in Q1 2025, an estimated $64.5K.
  • Citadel Advisors first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 11 quarters.
  • Citadel Advisors's Kalaris Therapeutics position peaked at $1.06M in Q3 2020.
  • 32 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.